IN THE CLAIMS

Please cancel claims 60-66, 69, 74-75 and 81 without prejudice.

Please amend claims 17-18, 67-68, 70-73, 76, 78, 79 and 85 as follows:

1-16. (Cancel)

17. (Currently Amended) A polypeptide capable of specific binding to factor VIII and interference with the activity of factor VIII inhibitors, ~~which~~ wherein the polypeptide comprises ~~the variable part of the~~ a heavy chain variable part of a human antibody with factor VIII specificity and a light chain variable part of a human antibody ~~or a part thereof which at least includes the CDR3 region~~.

18. (Currently Amended) A polypeptide according to claim 17, wherein said polypeptide is a single chain Fv fragment comprising the heavy chain variable part of a human antibody with factor VIII specificity and a light chain variable part of a human antibody. ~~which essentially consists of (a) the CDR3 region of the variable part of the heavy chain of a human antibody with factor VIII specificity, (b) an antibody fragment containing the variable part of the heavy chain of a human antibody with factor VIII specificity, or (c) a single chain Fv fragment containing the variable part of the heavy chain of a human antibody with factor VIII specificity~~.

19. (Withdrawn) A polynucleotide in substantially isolated form, coding for a polypeptide according to claim 17 or 18.

20. (Previously Presented) A pharmaceutical composition for the treatment of factor VIII inhibition in a human individual, comprising a polypeptide according to claim 17 or 18 together with a pharmaceutically acceptable carrier.

21. (Withdrawn) A pharmaceutical composition according to claim 20, which further contains factor VIII or a substitute of factor VIII.

22. (Withdrawn) A method of treatment of factor VIII inhibition in a human individual, comprising administering to said individual a polypeptide according to claim 17 or 18.

23. (Withdrawn) A method of treatment of factor VIII inhibition in a human individual, comprising administering to said individual a polypeptide according to claim 17 or 18 together with factor VIII or a substitute of factor VIII.

24. (Withdrawn) A polynucleotide in substantially isolated form comprising a contiguous nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(b) a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(c) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII, and

(d) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII.

25. (Withdrawn) The polynucleotide according to claim 24, wherein said contiguous nucleotide sequence encodes a human antibody specific for factor VIII.

26. (Withdrawn) The polynucleotide according to claim 24, wherein said contiguous nucleotide sequence encodes a light chain of a human antibody specific for factor VIII.

27. (Withdrawn) The polynucleotide according to claim 24, wherein said contiguous nucleotide sequence encodes a heavy chain human antibody specific for factor VIII.

28. (Withdrawn) The polynucleotide according to claim 24, wherein said complementarity-determining region is a CDR3 region.

29. (Withdrawn) The polynucleotide according to claim 24, wherein the human antibody specific for factor VIII is of a class selected from the group consisting of IgA, IgD, IgE, IgG and IgM.

30. ((Withdrawn)) The polynucleotide according to claim 29, wherein the human antibody specific for factor VIII is an IgG.

31. (Withdrawn) The polynucleotide according to claim 30, wherein the human antibody specific for factor VIII is an IgG from subclass IgG4.

32. (Withdrawn) The polynucleotide according to claim 24, wherein the human antibody specific for factor VIII comprises an immunoglobulin chain selected from the group consisting of: an immunoglobulin heavy chain, an immunoglobulin light chain, a fragment of an immunoglobulin heavy chain and a fragment of an immunoglobulin light chain.

33. (Withdrawn) The polynucleotide according to claim 32, wherein the polynucleotide comprises a VH-gene segment.

34. (Withdrawn) The polynucleotide according to claim 33, wherein the VH-gene segment of the human antibody specific for factor VIII is derived from a VH-gene segment selected from the group consisting of: a segment derived from a DP-10 segment, a segment derived from a DP-14 segment, a segment derived from a DP-15 segment, a segment derived from a DP-31

segment, a segment derived from a DP-47 segment, a segment derived from a DP-49 segment and a segment derived from a DP-77 segment.

35. (Withdrawn) The polynucleotide according to claim 24, wherein the human antibody specific for factor VIII is a single chain antibody.

36. (Withdrawn) The polynucleotide according to claim 24, wherein the human antibody specific for factor VIII is specific for the heavy chain of factor VIII.

37. (Withdrawn) The polynucleotide according to claim 24, wherein the human antibody specific for factor VIII is specific for the light chain of factor VIII.

38. (Withdrawn) The polynucleotide according to claim 36, wherein the human antibody factor VIII is specific for a domain of the heavy chain of factor VIII selected from the group consisting of the A1 domain, the A2 domain and the B domain.

39. (Withdrawn) The polynucleotide according to claim 37, wherein the human antibody is specific for a domain of the light chain of factor VIII selected from the group consisting of the A3 domain, the C1 domain and the C2 domain.

40. (Withdrawn) The polynucleotide according to claim 37, wherein the human antibody specific for the light chain of factor VIII is scFv-EL14.

41. (Withdrawn) The polynucleotide according to claim 37, wherein the human antibody specific for the light chain of factor VIII is scFv-IT2.

42. (Withdrawn) The polynucleotide according to claim 24, wherein the human antibody specific for factor VIII neutralizes the activity of factor VIII inhibitors of haemophilia A patients.

43. (Withdrawn) The polynucleotide according to claim 42, wherein the factor VIII inhibitors of haemophilia A patients are antibodies specific for factor VIII.

44. (Withdrawn) The polynucleotide according to claim 43, wherein the factor VIII inhibitors of haemophilia A patients are antibodies specific for the A2 domain, the A3 or the C2 domain of factor VIII.

45. (Withdrawn) The polynucleotide according to claim 44, wherein the human antibody specific for factor VIII that neutralizes the activity of factor VIII inhibitors shields the sites of factor VIII bound by the inhibitors.

46. (Withdrawn) The polynucleotide according to claim 45, wherein the human antibody specific for factor VIII that neutralizes the activity of factor VIII inhibitors and shields the sites of factor VIII bound by the inhibitors is specific for the A3-C1 domain or the A2 domain of factor VIII.

47. (Withdrawn) The polynucleotide according to claim 24, wherein the contiguous nucleotide sequence is at least about eight nucleotides in length.

48. (Withdrawn) The polynucleotide according to claim 47, wherein the contiguous nucleotide sequence is at least about ten nucleotides in length.

49. (Withdrawn) The polynucleotide according to claim 47, further comprising a detectable label.

50. (Withdrawn) The polynucleotide according to claim 49, wherein the detectable label is a radioactive atom, a radioactive group, an enzyme, a fluorescent group, a luminescent group, a dye or biotin.

51. (Withdrawn) A kit comprising a polynucleotide in substantially isolated form comprising a contiguous nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(b) a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(c) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(d) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII;

wherein the kit further comprises a suitable container.

52. (Withdrawn) The kit according to claim 51, wherein the polynucleotide further comprises a detectable label.

53. (Withdrawn) The kit according to claim 52, wherein the detectable label is a radioactive atom, a radioactive group, an enzyme, a fluorescent group, a luminescent group, a dye or biotin.

54. (Withdrawn) The kit according to claim 51, comprising a first and a second polynucleotide; the first polynucleotide being a polynucleotide of (a) and the second polynucleotide being a polynucleotide of (b); or the first polynucleotide being a polynucleotide of (c) and the second polynucleotide being a polynucleotide of (d).

55. (Withdrawn) The kit according to claim 54,wherein the first and the second polynucleotides form a primer pair suitable for priming cDNA synthesis.

56. (Withdrawn) The kit according to claim 55,wherein the polynucleotide primer pair are each between about 20 nucleotides and about 36 nucleotides in length.

57. (Withdrawn) The kit according to claim 55, further comprising a polynucleotide probe comprising a contiguous nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(b) a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(c) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII, and

(d) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII;

wherein the polynucleotide probe hybridizes to a nucleotide sequence that occurs between but does not include the first or second polynucleotides of the primer pair.

58. (Withdrawn) A method for detecting a nucleic acid encoding a human antibody specific for factor VIII, comprising:

(i) providing a sample containing nucleic acids for testing,

(ii) contacting the sample with a polynucleotide probe under conditions suitable for selective hybridization of the polynucleotide probe with a complementary nucleotide sequence; wherein the polynucleotide probe comprises a contiguous nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(b) a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII,

(c) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII, and

(d) a nucleotide sequence that selectively hybridizes under stringent conditions to a nucleotide sequence complementary to a nucleotide sequence encoding a complementarity-determining region of a human antibody specific for factor VIII;

(iii) determining whether the polynucleotide probe is hybridized to a complementary nucleotide sequence in the sample.

59. (Withdrawn) The method according to claim 58, wherein the nucleic acids in the sample are amplified by polymerase chain reaction prior to step (ii) using a first and a second primer; wherein the first primer is a polynucleotide of (a) and the second primer is a polynucleotide of (b); or the first primer is a polynucleotide of (c) and the second primer is a polynucleotide of (d); wherein the polynucleotide probe hybridizes to a nucleotide sequence that occurs between but does not include the polynucleotide of the first primer or of the second primer.

60.-66. (Cancel)

67. (Currently Amended) The polypeptide according to claim 17 ~~66~~, wherein the human antibody is an IgG.

68. (Currently Amended) The polypeptide according to claim 17 ~~67~~, wherein the human antibody is an IgG from subclass IgG4.

69. (Cancel)

70. (Currently Amended) The polypeptide according to claim 17 ~~60~~, wherein the polypeptide specifically binds the heavy chain of factor VIII.

71. (Currently Amended) The polypeptide according to claim 17 ~~60~~ wherein the polypeptide specifically binds the light chain of factor VIII.

72. (Currently Amended) The polypeptide according to claim 17 ~~70~~, wherein the polypeptide ~~human antibody~~ specifically binds a domain of the heavy chain of factor VIII consisting of the A1 domain, the A2 domain and the B domain of factor VIII.

73. (Currently Amended) The polypeptide according to claim 17 ~~71~~, wherein the polypeptide specifically binds a region of the light chain of factor VIII consisting of the A3 domain, the C1 domain and the C2 domain of factor VIII.

74.-75. (Cancel)

76. (Currently Amended) The polypeptide according to claim 17 ~~60~~, wherein the polypeptide reduces the activity of factor VIII inhibitors of haemophilia A patients.

77. (Previously Presented) The polypeptide according to claim 76, wherein the factor VIII inhibitors of haemophilia A patients are antibodies specific for factor VIII.

78. (Currently Amended) The polypeptide according to claim 76 ~~77~~, wherein the factor VIII inhibitors of haemophilia A patients are antibodies specific for the A2 domain, the A3 domain or the C2 domain of factor VIII.

79. (Currently Amended) The polypeptide according to claim 76 ~~78~~, wherein the polypeptide that reduces the activity of factor VIII inhibitors of haemophilia A patients is specific for the A3-C1 domain or the A2 domain of factor VIII.

80. (Withdrawn) A polypeptide in substantially isolated form comprising a polypeptide that specifically binds an antibody specific for factor VIII, wherein the polypeptide comprises:

(i) an amino acid sequence from a complementarity-determining region of a human antibody;

(ii) an amino acid sequence that mimicks the binding of a complementarity-determining region of a human antibody;

(iii) a derivative of an amino acid sequence from a complementarity-determining region of a human antibody.

81. (Cancel)

82. (Withdrawn) The pharmaceutical composition of claim 81, further comprising factor VIII or a compound with factor VIII activity.

83. (Withdrawn) A method of treatment of factor VIII inhibition in a human individual, comprising administering a polypeptide that specifically binds factor VIII, or a polypeptide that specifically binds an antibody specific for factor VIII, wherein the polypeptide comprises:

(i) an amino acid sequence from a complementarity-determining region of a human antibody;

(ii) an amino acid sequence that mimicks the factor VIII-binding of a complementarity-determining region of a human antibody; or

(iii) a derivative of an amino acid sequence from a complementarity-determining region of a human antibody.

84. (Withdrawn) The method of treatment according to claim 83, wherein the polypeptide is administered together with factor VIII or a compound with factor VIII activity.

85. (Currently Amended) A method of producing a ~~recombinant~~ polypeptide capable of specific binding to factor VIII and interference with the activity of ~~antibody, antibody fragment or derivative thereof specific for~~ factor VIII inhibitors, wherein the polypeptide comprises a heavy chain variable part of a human antibody with factor VIII specificity and a light chain variable part of a human antibody, the method comprising:

(i) providing a polynucleotide encoding said polypeptide;

~~(i)~~ (ii) ~~providing~~ preparing a recombinant vector containing ~~in a suitable host cell; the vector comprising a polynucleotide encoding~~ said polynucleotide ~~polypeptide~~ operably linked to a control sequence ~~for expression~~ capable of expressing the polynucleotide ~~from the vector~~ in ~~the~~ a host cell; ~~and~~

~~(ii)~~ (iii) ~~expressing the polypeptide in the host cell.~~ transforming the host cell with said recombinant vector; and

(iv) expressing said polypeptide in said host cell.

86. (Previously Presented) The method according to claim 85, further comprising isolating the polypeptide.